Next Generation Cancer Treatment Killing Tumors From The Inside Out
.png/:/cr=t:0%25,l:0%25,w:100%25,h:100%25/rs=w:1233,cg:true)
Precision Radionuclide Therapy™ is a next-generation, safer, less invasive cancer treatment for small and large animals.
Welcome to IsoPet®
Our Cancer Treatment
Meet Our Veterinarians & REgional Clinics
Meet Our Veterinarians & REgional Clinics
Our patented Precision Radionuclide Therapy (PRnT)™ is changing the way cancer is treated in animals. Currently we treat cats, dogs and horses in 8 regional clinics across the USA.
Meet Our Veterinarians & REgional Clinics
Meet Our Veterinarians & REgional Clinics
Meet Our Veterinarians & REgional Clinics
Our Certified IsoPet® Regional clinics and veterinarians have years of experience and are passionate about providing the best care for your pet.
Can IsoPet® save your pet's life?
Early Detection Is Key
What You Can Do:
Know Your Pet’s Body: Regularly petting and grooming your pet can help you become familiar with their body and notice any new lumps or changes sooner.
Make an appointment with your vet: If you find a lump, don’t wait. Have it checked by your trusted veterinarian as soon as possible. Even if it turns out to be nothing serious, it’s better to be safe. IsoPet® is a new treatment option your vet may not be aware of.
If the lump is cancer:
Act Quickly for Improved Outcomes: Early detection often leads to better treatment outcomes. This is because treatments can be less aggressive when the condition is caught early, reducing the risk of complications and side effects. Contact us directly if you have any questions at info@vivosinc.com
Cost Savings: While it might seem counterintuitive, early detection can lead to cost savings. Treating a disease in its advanced stages can be more complicated and expensive.
IsoPet® could save your pet's life.
"Precision Radionuclide Therapy™️ (PRnT) is a next generation, same day cancer treatment for animals." "We have compelling evidence that IsoPet® will kill the primary tumors in a single SAME-DAY therapy with very high therapeutic dose and minimal collateral damage"
Dr. Mike Korenko, Sc.D. President & CEO of Vivos Inc.